TIDMIMM

RNS Number : 6692X

Immupharma PLC

31 August 2022

31 August 2022

ImmuPharma plc

("ImmuPharma" or the "Company")

FDA response for Type C Meeting - update

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announced on 7 July 2022 that its US partner for Lupuzor(TM) (P140), Avion Pharmaceuticals ("Avion"), had advised that it had received Type C Meeting confirmation from the Food and Drug Administration ("FDA").

It was announced at that time that : the statement of purpose, objectives, and proposed agenda of the Type C meeting have been agreed with the FDA, that the FDA also agreed that written responses to the agenda items would be the most appropriate means for responding and that a face to face meeting was not required, and that the agreed date from the FDA for providing its written responses was 29 August 2022.

As of 30 August 2022, Avion has not yet received the written response from the FDA. The Company is in close contact with Avion and have been advised that the FDA is experiencing general delays in meeting response dates and that this is not specific to Avion and the Type C meeting for Lupuzor(TM) (P140). The Company will notify the market as soon as practicable once a response from the FDA has been received.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                      + 44 (0) 207 152 4080 
   Lisa Baderoon, Head of Investor Relations    + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)    +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                 +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Alora Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFFFEITEIIVIF

(END) Dow Jones Newswires

August 31, 2022 02:01 ET (06:01 GMT)

Grafico Azioni Immupharma (AQSE:IMM.GB)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Immupharma
Grafico Azioni Immupharma (AQSE:IMM.GB)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Immupharma